We are live on ! Find out more

LifeMD

LFMD

Market cap $147M

3.05 USD

+0.02

0.66%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

3.10

+0.05

1.64%

1 day

0.66%

5 days

0.66%

1 month

-9.76%

3 months

-37.76%

6 months

-24.88%

Year to date

-12.61%

1 year

-48.22%

5 years

-56.37%

10 years

-61.15%

About: LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.

Employees: 384

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 14.3%

Neutral 71.4%

Negative 14.3%

LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript

LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript

LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript

LifeMD Q2 Earnings Call Highlights

LifeMD NASDAQ: LFMD reported second-quarter revenue of $47.3 million, within its prior guidance range, while posting an adjusted EBITDA loss of approximately $3.5 million as elevated customer acquisition costs and a lower introductory price for branded GLP-1 care pressured profitability.

LifeMD Q2 Earnings Call Highlights

Zacks Investment Research

LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates

LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.06 per share a year ago.

LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates

UPDATE - LifeMD Reports Second Quarter 2026 Results

UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47.3 million, within the Company's guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.

UPDATE - LifeMD Reports Second Quarter 2026 Results

LifeMD to Report Second Quarter 2026 Financial Results on August 5

NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and six months ended June 30, 2026, after the close of the U.S. financial markets on August 5, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time.

LifeMD to Report Second Quarter 2026 Financial Results on August 5

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on July 15, 2026, to holders of record at the close of business on July 3, 2026.

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, launching in July 2026 in 37 states

LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

LifeMD Appoints Umesh Sripad as Chief Technology Officer

Seasoned Technology Executive Brings More Than Two Decades of Large-Scale Digital Transformation Experience to Support LifeMD's Next Phase of Growth Seasoned Technology Executive Brings More Than Two Decades of Large-Scale Digital Transformation Experience to Support LifeMD's Next Phase of Growth

LifeMD Appoints Umesh Sripad as Chief Technology Officer

LifeMD to Participate in Upcoming Investor Conferences

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading platform for virtual primary care services, today announced that management will be participating in two upcoming investor conferences.

LifeMD to Participate in Upcoming Investor Conferences

LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript

LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript

LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™